Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, GlaxoSmithKline Pharmaceuticals's average EBITDA Per Share Growth Rate was 12.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 20.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of GlaxoSmithKline Pharmaceuticals was 31.90% per year. The lowest was -10.90% per year. And the median was 6.60% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
GlaxoSmithKline Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms
NSE:GLAXO vs LLY, JNJ, ABBV: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlaxoSmithKline Pharmaceuticals 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.70% mean?
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) has a 3-Year EBITDA Growth Rate of 17.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. This is 168% above median its historical median of 6.60. According to the industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #283 out of 808 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is GlaxoSmithKline Pharmaceuticals' 3-Year EBITDA Growth Rate too high?
GlaxoSmithKline Pharmaceuticals' current 3-Year EBITDA Growth Rate of 17.70% is 168% above median its 10-year median of 6.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. GlaxoSmithKline Pharmaceuticals' value of 17.70% is 101.1% above this industry median. Based on the distribution chart, GlaxoSmithKline Pharmaceuticals ranks #283 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, GlaxoSmithKline Pharmaceuticals has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GlaxoSmithKline Pharmaceuticals' 3-Year EBITDA Growth Rate compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, GlaxoSmithKline Pharmaceuticals ranks #283 out of 808 companies for 3-Year EBITDA Growth Rate. This puts GlaxoSmithKline Pharmaceuticals in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.80. GlaxoSmithKline Pharmaceuticals' value of 17.70% is 101.1% above this benchmark. While the company's 10-year median is 6.60 vs. the industry median of 8.80, GlaxoSmithKline Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GlaxoSmithKline Pharmaceuticals's current 3-Year EBITDA Growth Rate of 17.70% is 101.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for GlaxoSmithKline Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GlaxoSmithKline Pharmaceuticals's current 3-Year EBITDA Growth Rate is 17.70%, which is 168% above median its own 10-year median of 6.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlaxoSmithKline Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,727.86, compared to a current price of ₹2,931.70 — trading 7.5% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.70%, which is 168% above median its 10-year median of 6.60 and 101.1% above the Drug Manufacturers industry median of 8.80. GlaxoSmithKline Pharmaceuticals' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For GlaxoSmithKline Pharmaceuticals (NSE:GLAXO), the current 3-Year EBITDA Growth Rate is 17.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Overvalued in 2026?
Based on GuruFocus' analysis, GlaxoSmithKline Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹2,931.70 is trading 7.5% above its estimated GF Value™ of ₹2,727.86.
GuruFocus considers GlaxoSmithKline Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:GLAXO:
3-Year EBITDA Growth Rate: 17.70% (168% above median its 10-year median of 6.60)
GF Value™: ₹2,727.86 vs. price of ₹2,931.70 (7.5% above fair value)
Industry Position: 101.1% above the Drug Manufacturers median (#283 of 808)
No single metric tells the full story. See the NSE:GLAXO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GlaxoSmithKline Pharmaceuticals Ltd is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals. It is healthcare organisation focused on uniting science, technology and talent to get ahead of disease. The company's product portfolio comprises a broad range of General Medicines which includes anti-infectives, pain management, vitamins, minerals, nutritionals, hormones, dermatologicals, vaccines for both children and adults, and specialty medicines for respiratory and oncology. Its focused brands are Augmentin, Ceftum, Flutivate, T-bat, Betnovate, Neosporin, Tenovate, Physiogel, Calpol and Calpol T. The company has single reportable segment. The company has presence in India, and also Outside India. It generates majority of revenue from India.
78GF Score
Get the complete analysis for NSE:GLAXO
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAXO has been successfully added to your 
